查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1197710

神经诊断市场 - COVID-19 的增长、趋势、影响和预测 (2023-2028)

Neurodiagnostics Market - Growth, Trends, and Forecasts (2023 - 2028)
出版日期: | 出版商: Mordor Intelligence | 英文 115 Pages | 商品交期: 2-3个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

简介目录

神经诊断市场预计在预测期内 (2023-2028) 的复合年增长率为 7.5%。

由于世界各国政府实施的封锁限制，COVID-19 大流行的出现减少了对医院和诊断中心的访问，减少了包括全球诊断和治疗在内的所有程序。影响了神经诊断市场。 此外，许多研究报告了 COVID-19 对神经系统疾病患者的不良影响，这也有望影响研究市场。 例如，根据国家生物技术信息中心 2021 年 7 月发表的一篇论文，“阿尔茨海默氏病和帕金森氏病预测不同的 COVID-19 结果。”英国生物银行的一项研究证实，患有痴呆症的人死于 COVID 的风险最高-19.因此，在 COVID-19 大流行期间延迟诊断这些疾病但是，随着服务和程序的恢復以及诊断中心的开放，神经诊断市场将在预测期内充分发挥其潜力。期待得到它回来。

神经系统疾病患病率上升、老年人口不断增加、神经诊断学技术进步以及对疾病早期诊断意识的提高是神经诊断学市场的主要驱动力。

阿尔茨海默病、肌萎缩性侧索硬化症、亨廷顿舞蹈病、帕金森病和脊髓性肌萎缩症等神经系统疾病患病率的上升是预测期内推动神经诊断市场需求的一个重要因素。 例如，根据世界卫生组织 2021 年 9 月的报告，全球约有 5500 万人患有痴呆症，每年报告的病例近 1000 万例。 同样，根据 2021 年 11 月国家生物技术信息中心一份题为“亨廷顿舞蹈病的流行”的报告，亨廷顿舞蹈病的患病率约为每 10 万人 10 例，在北美、西北欧、中东和澳大利亚都有发现. 高流行率在 在这些地区，估计每 100,000 人中有 5.96 到 13.70 人。 另一方面，在亚洲，患病率估计为每 100,000 人 0.41-0.70。

随着神经系统疾病在世界范围内日益流行，政府和非政府组织正在大力投资开发诊断和治疗方法，并为各种神经系统疾病和意识计划提供资金，这可能会促进市场增长。 例如，2021 年 1 月，Life Science Partners (LSP) 启动了 1.5 亿欧元的“LSP 痴呆症基金”，致力于抗击神经退行性疾□□病。 该基金将专注于痴呆症药物和医疗技术开发的所有阶段，以治疗患者的神经系统疾病。

但是，诊断和成像系统的高成本可能会阻碍市场增长。

神经诊断市场趋势

诊断和成像系统领域预计将占据主要市场份额

推动诊断和成像领域发展的主要因素包括神经系统疾病患病率上升、医学成像中先进技术的日益普及以及人口老龄化。

人口中神经系统疾病负担的增加增加了对神经诊断设备的需求，进一步推动了预测期内的市场增长。 例如，根据印度公共卫生基金会 2021 年 7 月发表的论文《印度神经系统疾病的负担》，随着人口老龄化，印度非传染性神经系统疾病的患病率正在增加。 中风、头痛问题和癫痫也是印度神经系统疾病的主要原因。 据同一消息来源称，2019 年中风导致 699,000 人死亡，占印度所有死亡人数的 7.4%。

正在开发新的治疗和诊断模型，以提供准确的结果，帮助及早发现疾病，并降低多种疾病的治疗成本。 随着可支配收入的增加，人们越来越有能力获得诊断成像以早期发现疾病。

此外，越来越多的公司专注于开发创新成像产品以实现更好的早期检测，这也促进了市场增长。 例如，2021 年 11 月，飞利浦在芝加哥举行的北美放射学会 (RSNA) 年会上推出了其新的人工智能驱动的磁共振产品组合。 同样，2021 年 3 月，日立医疗系统公司在 2021 年欧洲放射学会开幕式上宣布了两款配备工作流解决方案“SynergyDrive”的新型永久开放式 MRI 系统。 2020 年 8 月，GE Healthcare 宣布了三项新技术 SIGNA 7.0T 和 SIGNA UHP 3.0，以实现神经学研究并加速临床应用，以促进我们对阿尔茨海默病和创伤性脑损伤的认识。T，MAGNUS 宣布。

因此，神经系统疾病的日益流行以及对开发先进诊断和成像系统的关注有望推动市场增长。

北美将占据很大的市场份额，预计在预测期内也会如此

北美受到神经系统疾病患病率上升、人口老龄化、强大的医疗基础设施、高昂的医疗保健成本以及该地区越来越多的主要市场参与者不断发展和推出先进诊断设备的困扰. 由于其存在等原因，预计将在全球神经诊断市场占有较大的市场份额。

神经系统疾病患病率上升是推动该地区市场增长的关键因素。 例如，2021年6月，加拿大阿尔茨海默氏症协会首席科学官在接受采访时表示，“未来10年，加拿大预计将有超过100万人患上痴呆症。” 这表明北美地区阿尔茨海默氏病患病率的增加预计将增加对诊断和成像系统的需求，这可能会在预测期内进一步推动市场增长。 同样，根据帕金森基金会公布的数据，2021 年和 2020 年美国估计有 930 万帕金森病患者，预计到 2030 年这一数字将上升到 120 万。

此外，该地区不断增长的老年人口很可能会增加阿尔茨海默病和帕金森病等与年龄相关的神经退行性疾□□病的易感性，加重神经系统疾病的负担。 例如，根据阿尔茨海默氏症协会 2021 年 3 月的一份报告，美国约有 620 万 65 岁以上的人患有阿尔茨海默氏症相关痴呆症，预计到 2060 年这一数字将上升至 1380 万。

此外，该地区越来越多的诊断产品推出也将有助于预测期内的市场增长。 例如，2021 年 12 月，Fujifilm Healthcare Americas Corporation 在芝加哥举行的北美放射学会 (RSNA) 上宣布了先进的高场开放式 MRI 系统“Velocity MRI System”。

因此，预计在预测期内，老年人口的增加、神经系统疾病负担的增加以及产品发布的增加将推动市场扩张。

其他福利。

  • Excel 格式的市场预测 (ME) 表
  • 3 个月的分析师支持

内容

第1章介绍

  • 研究假设和市场定义
  • 调查范围

第2章研究方法论

第 3 章执行摘要

第4章市场动态

  • 市场概览
  • 市场驱动因素
    • 神经系统疾病的发病率增加
    • 新诊断技术的采用范围扩大
  • 市场製约因素
    • 诊断成本高
  • 波特的五力分析
    • 新进入者的威胁
    • 买方/消费者议价能力
    • 供应商的议价能力
    • 替代品的威胁
    • 竞争公司之间的敌对关係

第 5 章市场细分

  • 按产品类型
    • 临床测试设备
    • 诊断/成像系统
    • 试剂和耗材
  • 最终用户
    • 医院和诊所
    • 诊断研究所/诊断影像中心
    • 其他最终用户
  • 按地区
    • 北美
      • 美国
      • 加拿大
      • 墨西哥
    • 欧洲
      • 德国
      • 英国
      • 法国
      • 意大利
      • 西班牙
      • 其他欧洲地区
    • 亚太地区
      • 中国
      • 日本
      • 印度
      • 澳大利亚
      • 韩国
      • 其他亚太地区
    • 中东
      • 海湾合作委员会
      • 南非
      • 其他中东地区
    • 南美洲
      • 巴西
      • 阿根廷
      • 其他南美洲

第6章竞争格局

  • 公司简介
    • Canon Medical Systems Corporation
    • Siemens Healthineers
    • Koninklijke Philips N.V.
    • Thermo Fisher Scientific, Inc
    • Fujifilm Corporation
    • Natus Medical Incorporated
    • Lifelines Neuro Company
    • Advanced Brain Monitoring, Inc
    • Nihon Kohden Corporation
    • Hoffmann-La Roche Ltd
    • GE Healthcare
    • Mitsar Co. LTD

第7章 市场机会与今后动向

简介目录
Product Code: 68292

The Neurodiagnostics Market is expected to register a CAGR of 7.5% during the forecast period (2023 - 2028).

The emergence of the COVID-19 pandemic had its impact on the neurodiagnostic market as all the procedures, including diagnostic and therapeutic around the world were impacted due to the decline in visits to hospitals and diagnostic centers because of lockdown restrictions imposed by various governments globally. Further, many studies reported the negative impact of COVID-19 on patients with neurological disorders, which is also expected to impact the studied market. For instance, according to an article published by the National Center for Biotechnology Information, in July 2021, titled "Alzheimer's and Parkinson's diseases predict different COVID-19 outcomes: A UK Biobank study", it was observed that the patients with dementia have the highest mortality risk from COVID-19. Thus, the delay in the diagnosis of such diseases during the COVID-19 pandemic has further increased the risk for the patients and negatively impacted the market growth. However, with the resumed services and procedures, and the opening of the diagnostic centers, the neurodiagnostic market is expected to regain its full potential over the forecast period.

The increasing prevalence of neurological disorders, rise in the geriatric population, technological advancements in neurodiagnostic, and growing awareness regarding early diagnosis of diseases are the key driving factors in the neurodiagnostic market.

The rising prevalence of neurological disorders such as Alzheimer's disease, Amyotrophic lateral sclerosis, Huntington's disease, Parkinson's disease, and spinal muscular atrophy is the key factor driving the demand for the neurodiagnostic market over the forecast period. For instance, For according to the September 2021 report of the World Health Organization, about 55 million people around the world are living with dementia, and nearly 10 million cases are reported every year. Similarly, as reported in National Center for Biotechnology Information, in November 2021, titled "Prevalence of Huntington's Disease", it has been observed that the prevalence of Huntington's disease is around 10 cases per 100,000 people, with a higher prevalence in North America, North-western Europe, the Middle East, and Australia. In these regions, the estimates range from 5.96 to 13.70 cases per 100,000 people. Whereas in Asia, the prevalence is estimated to be 0.41-0.70 cases per 100,000 people.

With the growing prevalence of neurological diseases around the world, government and non-government entities are investing heavily in the development of diagnostics and therapeutics for the treatment, as well as increasing funding and awareness programs for various neurological disorders, which may augment the growth of the market. For instance, in January 2021, Life Sciences Partners (LSP) launched the EUR 150 million LSP Dementia Fund, which is dedicated to combating neurodegenerative diseases. This fund will focus on all stages of dementia drugs and Medtech development to treat neurological diseases in patients.

However, the high cost of diagnostic and imaging systems is likely to hinder the growth of the market.

Neurodiagnostics Market Trends

Diagnostic and Imaging Systems Segment is Expected to Hold a Major Market Share

The major factors propelling the growth of the diagnostic and imaging segment include the rising prevalence of neurological disorders, increasing adoption of advanced technologies in medical imaging, and the rising geriatric population.

The increasing burden of neurological disorders among people is increasing the demand for neurodiagnostic devices, which further increases the market growth over the forecast period. For instance, according to a paper published by the Public Health Foundation of India in July 2021, titled " Burden of Neurological disorders in India", the prevalence of non-communicable neurological illnesses is rising in India, owing to the country's aging population. In addition, in India, stroke, headache problems, and epilepsy are the primary causes of neurological illnesses. As per the same source, stroke resulted in the deaths of 699,000 people in 2019, accounting for 7.4% of all deaths in India.

New therapeutic and diagnostic models are being developed that deliver precise results, aid in early disease detection, and reduce the cost of treating various diseases. With the increasing disposable income, people are becoming capable enough to have access to imaging procedures for the early detection of diseases.

Moreover, the increasing company focus on developing innovative imaging and diagnostic products for better and early detection are also contributing to the growth of the market. For instance, in November 2021, Philips launched a new Artificial intelligence-enabled Magnetic Resonance portfolio at the Radiological Society of North America (RSNA) annual meeting in Chicago. Similarly, in March 2021, Hitachi Medical Systems launched two new permanent open MRI systems that are equipped with the SynergyDrive workflow solution at the start of the 2021 European Congress of Radiology. In August 2020, GE Healthcare showcased its three new technologies, SIGNA 7.0T, SIGNA UHP 3.0T, and MAGNUS, to enable neuro research to better understand Alzheimer's disease and traumatic brain injury as well as accelerate clinical translation.

Thus, the increasing prevalence of neurological diseases and the company's focus on developing well-advanced diagnostic and imaging systems are likely to increase the market growth.

North America is Expected to Hold a Significant Share in the Market and Expected to do Same in the Forecast Period

North America is expected to hold a major market share in the global neurodiagnostic market due to the increasing prevalence of neurological disorders, rising geriatric population, presence of robust healthcare infrastructure, high healthcare spending, and presence of major market players continuously evolving and launching advanced diagnostics devices in the region.

The rising prevalence of neurological diseases is the key factor driving the growth of the market in the region. For instance, in June 2021, in an interview, the Chief Science Officer of the Alzheimer Society of Canada stated that "Over the next 10 years, it was anticipated that more than one million people in Canada will be living with dementia." This indicates that the increasing prevalence of Alzheimer's in the North American region is expected to increase the demand for diagnostic and imaging systems, which may further drive the market growth over the forecast period. Similarly, according to the data published by the Parkinson's Foundation, in 2021, an estimated 9,30,000 people were living with Parkinson's disease in the United States 2020, and this number is predicted to increase to 1,2 million by 2030.

Also, the growing geriatric population in the region is expected to increase the burden of neurological disorders, as the geriatric population is more prone to neurodegenerative diseases like Alzheimer's and Parkinson's, age-associated diseases. For instance, according to the March 2021 report of the Alzheimer's Association, approximately 6.2 million people of age 65 years and more are living with Alzheimer's-related dementia in the United States, and it is projected that this number will increase to 13.8 people by 2060.

Moreover, the increasing diagnostic product launches in the region are also contributing to the growth of the market over the forecast period. For instance, In December 2021, Fujifilm Healthcare Americas Corporation presented an advanced high-field open MRI system, Velocity MRI System, at the Radiological Society of North America (RSNA) conference in Chicago.

Hence, the increasing geriatric population, rising burden of neurological disease, and increased product launches are likely to increase the market expansion over the forecast period.

Neurodiagnostics Market Competitor Analysis

The Neurodiagnostics Market is consolidated and consists of several major players operating in specific segments such as imaging and clinical diagnostics etc. In terms of market revenue, a few of the major players are currently dominating the market. Some of the companies which are currently dominating the market are GE Healthcare, Siemens Healthineers, Philips Healthcare, Thermo Fisher Scientific, Inc, Hitachi, Ltd, Natus Medical Incorporated, Lifelines Neuro Company, Advanced Brain Monitoring, Inc, and Nihon Kohden Corporation.

Additional Benefits:

  • The market estimate (ME) sheet in Excel format
  • 3 months of analyst support

TABLE OF CONTENTS

1 INTRODUCTION

  • 1.1 Study Assumptions and Market Definition
  • 1.2 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Increasing Incidence of Neurological Diseases
    • 4.2.2 Growing Adoption of Novel Diagnostic Technologies
  • 4.3 Market Restraints
    • 4.3.1 High Cost of Diagnosis
  • 4.4 Porter's Five Forces Analysis
    • 4.4.1 Threat of New Entrants
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Bargaining Power of Suppliers
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION

  • 5.1 By Product Type
    • 5.1.1 Clinical Testing Instruments
    • 5.1.2 Diagnostic and Imaging Systems
    • 5.1.3 Reagents and Consumables
  • 5.2 By End-User
    • 5.2.1 Hospitals and Clinics
    • 5.2.2 Diagnostic Laboratories and Imaging Centers
    • 5.2.3 Other End-Users
  • 5.3 Geography
    • 5.3.1 North America
      • 5.3.1.1 United States
      • 5.3.1.2 Canada
      • 5.3.1.3 Mexico
    • 5.3.2 Europe
      • 5.3.2.1 Germany
      • 5.3.2.2 United Kingdom
      • 5.3.2.3 France
      • 5.3.2.4 Italy
      • 5.3.2.5 Spain
      • 5.3.2.6 Rest of Europe
    • 5.3.3 Asia-Pacific
      • 5.3.3.1 China
      • 5.3.3.2 Japan
      • 5.3.3.3 India
      • 5.3.3.4 Australia
      • 5.3.3.5 South Korea
      • 5.3.3.6 Rest of Asia-Pacific
    • 5.3.4 Middle-East
      • 5.3.4.1 GCC
      • 5.3.4.2 South Africa
      • 5.3.4.3 Rest of Middle-East
    • 5.3.5 South America
      • 5.3.5.1 Brazil
      • 5.3.5.2 Argentina
      • 5.3.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE

  • 6.1 Company Profiles
    • 6.1.1 Canon Medical Systems Corporation
    • 6.1.2 Siemens Healthineers
    • 6.1.3 Koninklijke Philips N.V.
    • 6.1.4 Thermo Fisher Scientific, Inc
    • 6.1.5 Fujifilm Corporation
    • 6.1.6 Natus Medical Incorporated
    • 6.1.7 Lifelines Neuro Company
    • 6.1.8 Advanced Brain Monitoring, Inc
    • 6.1.9 Nihon Kohden Corporation
    • 6.1.10 Hoffmann-La Roche Ltd
    • 6.1.11 GE Healthcare
    • 6.1.12 Mitsar Co. LTD

7 MARKET OPPORTUNITIES AND FUTURE TRENDS